On multivariate analysis, more favourable histology (G3EC), younger age, and earlier stage were independent predictors of improved survival.
In multivariate analysis, a favourable change in fat consumption (P = 0.007) and lipid-lowering medication (P < 0.001) were associated with decreasing cholesterol levels.
Multivariate analysis confirmed the favourable effect of receiving treatment within a clinical trial (HR 2.6, 95% CI: 1.1 5.7, P=0.022) together with having mutated IGHV genes (HR 3.9, 95% CI: 1.6 10.1, P=0.004) and a wild-type TP53 gene (HR 2.9, 95% CI: 1.3 6.2, P=0.008; Figure 1).
LN: Lymph Node; EBRT: External Beam Radiation Therapy Using multivariate analysis, we identified several favourable predictors associated with an improved overall survival, which included age < 60 years, a T1 or T2 tumour stage, absence of synchronous LN metastases, and EBRT.
In addition, multivariate analysis revealed that the favourable genotype (low TXR1/high TSP1 expression) was an independent prognostic factor for increased PFS and survival, and was associated with a 51 and 63% reduction of the risk for progression or death, respectively.
The principal results of univariate analysis are shown in Table 2. Multivariate analysis demonstrated an independent favourable impact on survival for occurrence of a skin reaction (HR=0.28, 95% CI 0.12 0.66; P=0.004) and an independent negative impact on survival for a level of CYFRA 21-1 higher than 3.5 ng ml−1 (HR=2.45, 95% CI 1.13 5.29; P=0.02).
On multivariate analysis, factors associated with a favourable outcome were a solitary site and single metastasis, complete resection of the first metastasis, a long disease-free interval and a metachronous presentation.
Nuclear localisation was associated with favourable prognosis in multivariate analysis.
Multivariate analysis revealed DDR1 is an independent favourable predictor for prognosis independent of tumour differentiation, stage, histology, and patient age.
LRT was an independent factor of favourable outcome in multivariate analysis, taking into account the main cancer-related prognostic factors (hazard ratio, 0.70 [95%CI 0.58-0.85]; p = 0.0002).
